Skip to content
Announcement:

The results of a recent collaboration between Sanofi, GSK, Lilly, Vesalius Therapeutics, Leiden University, Heidelberg University, ElmorePathology and Newcells aimed at enhancing safety assessments has just been published. Find out how rat kidney gene co-expression networks has enabled biomarker identification and human translation for renal safety assessments.

Amy Mawdesley

Business Development Manager

Amy is a Business Development Manager at Newcells Biotech. After earning a PhD from Newcastle University, she worked as a Research Associate in diagnostics before joining Newcells in 2022 as a Product Manager. She later transitioned into Business Development, where she focuses on fostering strong client relationships and supporting the design of customized projects to address key business challenges. She is particularly passionate about reducing reliance on animal models by utilizing advanced in vitro systems to promote more ethical and efficient research. At Newcells, she helps clients leverage innovative in vitro tools to gain deeper insights into drug interactions with lung, kidney, and retina tissues.

Get our latest updates straight to your inbox

Book a Call